First Trust Direct Indexing L.P. Buys 86 Shares of DaVita Inc. (NYSE:DVA)

First Trust Direct Indexing L.P. increased its stake in DaVita Inc. (NYSE:DVA) by 2.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,051 shares of the company’s stock after acquiring an additional 86 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in DaVita were worth $500,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Blue Trust Inc. increased its stake in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. bought a new stake in DaVita during the 2nd quarter valued at $43,000. Versant Capital Management Inc increased its stake in DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares in the last quarter. Friedenthal Financial bought a new stake in DaVita during the 2nd quarter valued at $48,000. Finally, Point72 Hong Kong Ltd bought a new stake in DaVita during the 2nd quarter valued at $68,000. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last three months. 2.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Price Performance

Shares of NYSE:DVA opened at $141.59 on Monday. The company’s 50-day moving average is $157.71 and its 200 day moving average is $146.17. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.12 and a current ratio of 1.37. The company has a market capitalization of $11.61 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 0.79 and a beta of 0.89. DaVita Inc. has a fifty-two week low of $76.64 and a fifty-two week high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $2.85 earnings per share. On average, equities research analysts forecast that DaVita Inc. will post 9.73 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.